0000000000598454

AUTHOR

Yihua Zhao

showing 3 related works from this author

Lung function and long-term safety of tiotropium/olodaterol in East Asian patients with chronic obstructive pulmonary disease

2017

Background and purpose While the efficacy and safety of combined tiotropium and olodaterol in patients with COPD was established in a large clinical trial program, it is important to assess whether clinical data can be applied to geographic patient groups, particularly for East Asian patients who may have a different phenotypic profile to the global trial population. This study aimed to compare the lung function and safety profiles of tiotropium/olodaterol and monocomponents in East Asian and global populations from the TONADO® trials. Materials and methods In the replicate, double-blind, parallel-group, active-controlled, randomized, 52-week, Phase III TONADO studies, patients received tio…

MaleTime FactorsHealth StatusVital CapacityCholinergic AntagonistsPulmonary function testingPulmonary Disease Chronic Obstructivechemistry.chemical_compound0302 clinical medicineForced Expiratory Volume030212 general & internal medicineLungLung functionOriginal ResearchCOPDeducation.field_of_studypulmonary functionOlodaterolArea under the curveGeneral MedicineMiddle AgedhumanitiesBronchodilator AgentsDrug CombinationsTreatment OutcomeArea Under CurveFemaleChinamedicine.medical_specialtyPopulationInternational Journal of Chronic Obstructive Pulmonary Disease03 medical and health sciencesAsian PeopleDouble-Blind MethodInternal medicinemedicineHumansCOPDTiotropium BromideAdverse effecteducationAdrenergic beta-2 Receptor AgonistsAgedbusiness.industryRecovery of Functionmedicine.diseaseBenzoxazinesrespiratory tract diseasesClinical trial030228 respiratory systemchemistryQuality of Lifeadverse effectsTONADO®businesshuman activitiesInternational Journal of Chronic Obstructive Pulmonary Disease
researchProduct

P131 Efficacy of tiotropium and olodaterol combination in patients with COPD on β-blockers: Abstract P131 Table 1

2015

Rationale The efficacy and safety of a new once-daily combination with tiotropium (T), a long-acting muscarinic antagonist, and olodaterol (O), a long-acting β2-agonist, was established for the treatment of chronic obstructive pulmonary disease (COPD) in the TONADO studies ([NCT01431274][1]; [NCT01431287][2]). This analysis evaluates the efficacy of the combination in a subpopulation of patients receiving β-blockers in these studies. Methods Two replicate, randomised, double-blind, parallel-group, 52-week, Phase III trials assessed the efficacy and safety of T+O (2.5/5 μg; 5/5 μg; via Respimat® inhaler) once daily compared to the monocomponents. Key primary end-point data for the combined a…

Pulmonary and Respiratory MedicineTreatment interactionmedicine.medical_specialtyCOPDbusiness.industryInhalerOlodaterolArea under the curveUrologyMuscarinic antagonistmedicine.diseaseSurgerychemistry.chemical_compoundchemistrymedicineIn patientPatient groupbusinessmedicine.drugThorax
researchProduct

Efficacy of tiotropium and olodaterol fixed-dose combination in patients with COPD on β-blockers

2015

Introduction: The efficacy and safety of a new once-daily (QD) fixed-dose combination (FDC) with tiotropium (T), a long-acting muscarinic antagonist, and olodaterol (O), a long-acting β 2 -agonist, was established for the treatment of COPD in the TONADO studies (NCT01431274; NCT01431287). This analysis evaluates the efficacy of the FDC in a subpopulation of patients receiving β-blockers (BBs) in these studies. Methods: Two replicate, randomised, double-blind, parallel-group, 52-week, Phase III trials assessed the efficacy and safety of T+O FDC (2.5/5 μg; 5/5 μg; Respimat ® inhaler) QD compared to the monocomponents. Key primary end point data for the combined analysis of the replicate trial…

COPDmedicine.medical_specialtyRespimatbusiness.industryInhalerOlodaterolFixed-dose combinationMuscarinic antagonistmedicine.diseasechemistry.chemical_compoundchemistryInternal medicinemedicinePhysical therapyClinical endpointIn patientbusinessmedicine.drug5.1 Airway Pharmacology and Treatment
researchProduct